ReviewExpert opinion on drug delivery2011
Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis.
Review in Expert opinion on drug delivery, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 64 citations in OpenAlex.
- Hypertension, use of antihypertensive medications and breast cancer survival among Black women.Breast cancer research : BCR · 2026Article
- Old drugs, new challenges: reassigning drugs for cancer therapies.Cellular & molecular biology letters · 2025Review
- Phytochemicals Showing Antiangiogenic Effect in Pre-clinical Models and their Potential as an Alternative to Existing Therapeutics.Current topics in medicinal chemistry · 2024Review
- "Therapeutic advancements in nanomedicine: The multifaceted roles of silver nanoparticles".Biotechnology notes (Amsterdam, Netherlands) · 2024Review
- Vascular response patterns to targeted therapies in murine breast cancer models with divergent degrees of malignancy.Breast cancer research : BCR · 2023Article
- In vitro assessment of varying peptide surface density on the suppression of angiogenesis by micelles displaying αvβ3 blocking peptides.Journal of biomedical materials research. Part B, Applied biomaterials · 2023Article
- Development of L-Lysine-Loaded PLGA Microparticles as a Controlled Release System for Angiogenesis Enhancement.Pharmaceutics · 2023Article
- Gut Microbiota-Assisted Synthesis, Cellular Interactions and Synergistic Perspectives of Equol as a Potent Anticancer Isoflavone.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Long-Term Controlled Growth Factor Release Using Layer-by-Layer Assembly for the Development ofACS applied materials & interfaces · 2022Article
- Effect of composite biodegradable biomaterials on wound healing in diabetes.Frontiers in bioengineering and biotechnology · 2022Review
- MicroRNAs in laser-induced choroidal neovascularization in mice and rats: their expression and potential therapeutic targets.Neural regeneration research · 2021Article
- MicroRNAs as diagnostic and prognostic biomarkers of age-related macular degeneration: advances and limitations.Neural regeneration research · 2021Review
- Lipid Raft Association Stabilizes VEGF Receptor 2 in Endothelial Cells.International journal of molecular sciences · 2021Article
- Implantable anti-angiogenic scaffolds for treatment of neovascular ocular pathologies.Drug delivery and translational research · 2020Review
- 3D Bioprinting for Vascularized Tissue-Engineered Bone Fabrication.Materials (Basel, Switzerland) · 2020Review
- Microchannel network hydrogel induced ischemic blood perfusion connection.Nature communications · 2020Article
- Associations of microRNAs, Angiogenesis-Regulating Factors and CFH Y402H Polymorphism-An Attempt to Search for Systemic Biomarkers in Age-Related Macular Degeneration.International journal of molecular sciences · 2019Article
- Review
- Drug delivery systems and materials for wound healing applications.Advanced drug delivery reviews · 2018Review
- Tissue engineering strategies for the induction of angiogenesis using biomaterials.Journal of biological engineering · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
introductionAngiogenesis is essential to human biology and of great clinical significance. Excessive or reduced angiogenesis can result in, or exacerbate, several disease states, including tumor formation, exudative age-related macular degeneration (AMD) and ischemia. Innovative drug delivery systems can increase the effectiveness of therapies used to treat angiogenesis-related diseases. AREAS COVERED: This paper reviews the basic biology of angiogenesis, including current knowledge about its disruption in diseases, with the focus on cancer and AMD. Anti- and proangiogenic drugs available for clinical use or in development are also discussed, as well as experimental drug delivery systems that can potentially improve these therapies to enhance or reduce angiogenesis in a more controlled manner. EXPERT OPINION: Laboratory and clinical results have shown pro- or antiangiogenic drug delivery strategies to be effective in drastically slowing disease progression. Further research in this area will increase the efficacy, specificity and duration of these therapies. Future directions with composite drug delivery systems may make possible targeting of multiple factors for synergistic effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.